Pharmacoeconomic review report: Tafamidis (Vyndaqel) (Pfizer Canada ULC) indication: for the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis, wild-type or hereditary, to reduce cardiovascular mortality and cardiovascular-related hospitalization
Mortality for patients in the "alive with transplant" health state was informed by survival data calculated from the International Society for Heart and Lung Transplantation registry
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
2020, April 2020
|
| Edition: | Final |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references